Scientists need a better understanding of the chemistry of radium to be able to target the isotope radium-223 (Ra-223) to cancer cells. Once delivered, Ra-223 can destroy those cells with alpha ...
Table 1. Clinical Characteristics of Patients Eligible versus Optimal for Radium 223 A significant increase in overall survival was observed across all patients treated with radium 223 (hazard ratio ...
Radium-223 dichloride (radium-223 for short, trade name: Xofigo) has been approved since November 2013 for men with advanced prostate cancer, in whom hormone blockade is no longer effective, and ...
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors Patients with bone metastatic CRPC ...
MUNICH -- Men with bone-predominant metastatic castration-resistant prostate cancer (mCRPC) had worse outcomes when radium-223 (Xofigo) was added to abiraterone (Zytiga) and prednisone, according to ...
Magnetic resonance imaging (MRI) is not routinely performed before initiating radium-223 to document spinal epidural disease. However, radium-223 decays to form α-particles with very short path ...
The novel radiopharmaceutical for prostate cancer, radium Ra223 dichloride (Xofigo), is equally effective whether or not the patient has previously received chemotherapy with docetaxel, a new analysis ...
DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Xofigo" drug pipelines has been added to ResearchAndMarkets.com's offering. Xofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback